A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs PRCL 02 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors PRCL Research Inc
- 09 Jul 2019 Status changed from active, no longer recruiting to completed.
- 24 Jun 2019 Planned End Date changed from 1 Jun 2019 to 1 Sep 2019.
- 23 May 2019 Planned End Date changed from 1 Aug 2019 to 1 Jun 2019.